Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02289950 |
| Title | A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer |
| Recruitment | Completed |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Morphotek |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ITA | GBR | ESP | DEU | BEL |